| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B65H29-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B65H29-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G07D11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G07D9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G07F7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G07F19-00 |
| filingDate |
1994-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1999-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97a832097f121776ffcec244bc7bb41f |
| publicationDate |
1999-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5904925-A |
| titleOfInvention |
Adjuvant for antigens, and process for making |
| abstract |
Adjuvants are disclosed for antigens such as viruses, bacteria and parasites, including their metabolic products or parts of the virus, bacteria and parasite structures for the immunization, as well as a process for producing such adjuvants and their uses. The object of the invention is to create adjuvants that in combination with vaccine antigens or with peptidoglycanes in histocompatible composition allow the defence mechanisms in the body to be stimulated to such a large extend that for the first time besides active immunoprophylaxis a even of weak antigens also a general and specific immunotherapy is made possible. The cost of producing the adjuvant should not exceed the usual cost and should ensure the applicability of the vaccine. In relatively weak immuno-incompetent phases of life, a combination of general immunoprophylaxis or the only use of the adjuvant should ensure a high immuno-competence. Residual effects of the adjuvant should not cause any problems. The disclosed adjuvants are oil-in-water emulsions. The oil phase consists of polydimethyl siloxanes and the aqueous phase substantially consists of a biocompatible salt solution. The oil phase is stabilised in the water phase by means of a complex emulsifying agent with HLB value from 9 to 16. The complex emulsifying agent is a combination of aliphatic alcohols of sorbitol with 10 to 100 carbon atoms in the chain and/or of glycerol fatty acid esters and polysorbates. The biocompatible salt solution is a phosphate-buffered sodium chloride solution with EDTA sodium. The combination further contains dimethylsulfoxide. A complete adjuvant is produced by adding peptidoglycanes based on species-specific St. Aureus strains and water-soluble natural and/or synthetic polymers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2005200643-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03011223-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8603482-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7915238-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007292418-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002076451-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7267963-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009104235-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005222182-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011217366-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009093019-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8691209-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03011223-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7833993-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6521776-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6551600-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009092639-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6835721-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7976852-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6290973-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007027111-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7560584-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9950055-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020139298-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003153532-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6288026-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007020232-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7666624-B2 |
| priorityDate |
1993-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |